Alliance will enhance cell and gene therapy pipelines from BRL Medicine from clinical trials to further expedite commercialization of innovative therapies.
To leverage Immatics' TCR platform with Moderna's mRNA technology across therapeutic modalities including bispecifics, cell therapy and cancer vaccines.
Recipharm will provide analytical and process development capabilities to support toxicology studies, as well as GLP manufacturing of lipid nanoparticles.
Will apply Shape’s AAVid capsid discovery platform and transgene engineering technology with Otsuka’s expertise in genetic payload design and ophthalmology.